Masson’s trichrome staining: the cell nuclei are blue-black, the cytoplasms (cell bodies) are mauve and the collagen fibers are green.
Credit: Riccardo Di Corato – laboratoire MSC (CNRS/Université Paris Diderot)
By combining, in a liposome, magnetic nanoparticles and photosensitizers that are simultaneously and remotely activated by external physical stimuli (a magnetic field and light), scientists obtained total tumor regression in mice.
Non-toxic when they are not activated, such therapies can also achieve a reduction in adverse effects. These results demonstrate the importance of multiple treatments.
One of the strategies employed to limit the adverse effects of cancer therapies is the development of nanocarrier systems that can convey active ingredients to target tumor cells. These are referred to as “physical” therapies when the active substances, molecules or nanoparticles, can be remotely activated by external physical stimuli — in this case by light or a magnetic field. In this context, the study team developed a new type of carrier that combines photosensitivity and magnetism. To achieve this, they first encapsulated magnetic nanoparticles in the inner compartment of a liposome in sufficient quantities to render it ultra-magnetic, before incorporating photosensitizers into its lipid bilayer, while preserving an optimum size for circulation in the blood.
These liposomes, containing magnetic nanoparticles and photosensitizers, were injected directly into the tumor in the mouse model. The scientists thus combined two techniques to achieve complete destruction of cancer cells. The first one, magnetic hyperthermia, consists in exciting the nanoparticles with a magnetic field to raise the temperature of the tumor and destroy it.. The second method, photodynamic therapy, is made possible by the photosensitizers, which, when activated, release reactive oxygen species that are toxic to tumor cells. These two physical therapies act in synergy on the activity of the proteins involved in apoptosis, or programmed cell death. Their combination thus induces total regression of the tumor, while a single therapy is not able to stop its growth.
Read more: Combining magnetism and light to fight cancer
The Latest on: Tumor regression
via Google News
The Latest on: Tumor regression
- The impact of mammographic screening on the subsequent breast cancer risk associated with biopsy-proven benign breast diseaseon March 5, 2021 at 3:48 am
Data on the risk of breast cancer following a (BBD) diagnosis were derived predominantly from populations of women biopsied before the widespread use of mamm ...
- A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer riskon March 4, 2021 at 9:02 am
Colorectal cancer prognosis is dependent on stage, and measures to improve early detection are urgently needed. Using prospectively collected plasma samples from the population-based Northern Sweden ...
- The Many Shades of KRAS: Investigators Seek to Exploit Heterogeneity in Mutationson March 3, 2021 at 7:04 am
KRAS has topped the most wanted list of therapeutic targets in oncology for decades, but it has resolutely resisted all efforts, garnering it a reputation as undruggable.
- Advanced Oral Therapy Adherence Among Patients With Prostate Canceron March 2, 2021 at 4:00 pm
Patients with prostate cancer who were non-adherent to advanced oral therapies experienced substantially higher health care resource utilization (HCRU) than those who were adherent, according to a ...
- Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting ...on March 2, 2021 at 1:24 pm
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the ...
- Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021on March 2, 2021 at 1:08 pm
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the ...
- Antibodies deplete cancer cells in mice and human cell lines; reach previously inaccessible targetson March 2, 2021 at 6:12 am
Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power ...
- FDA Says No To ATNX And CRMD, Morphic Jumps On IBD Trial Data, INO's REVEAL 1 Meets Goalson March 1, 2021 at 9:51 pm
FDA Sends Athenex Back to Drawing Board Shares of Athenex Inc. (ATNX) plunged over 54% on Monday to touch a new low, following the FDA's refusal to approve the company's oral Paclitaxel plus ...
- Studies reveal the promise of newly engineered bispecific antibodies against tumor cellson March 1, 2021 at 2:25 pm
Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power ...
- Whales’ Cancer Resistance ‘in Their Genes’on February 24, 2021 at 8:52 am
In general, when a creature has more cells in its body, they are expected to be more vulnerable to random mutations that can develop into cancer. Not true for cetacean creatures.
via Bing News
